- Human（2）
No data
- His Tag（1）
- His Tag & Avi Tag（1）
No data
- E. coli（2）
No data
- Biotin-labeled（1）
- Unconjugated（1）
No data
- RUO（2）
No data
- No（2）
No data
- 100ug/$450.00
- 1mg/$3215.00
No data
- 25ug/$415.00
- 200ug/$1705.00
No data
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Catenin beta-1 | Human Catenin beta-1 Protein, His Tag (MALS verified) |  Human | E. coli |  | MALSSDS-PAGE | $450.00 100ug |   | ||
| Catenin beta-1 | Avitag CA1-H81E3 | Biotinylated Human Catenin beta-1 Protein, His,Avitag™ (MALS verified) | Human | E. coli |  | MALSSDS-PAGE | $415.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CEQ-508 | CEQ-508 | Phase 2 Clinical | Marina Biotech | Adenomatous Polyposis Coli | Details |
| Foscenvivint | PRI-724; ICG-001; OP-724 | Phase 2 Clinical | Prism Pharma Co Ltd, University Of Southern California | Colorectal Neoplasms; Hepatitis B; Hepatitis C; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Cirrhosis, Biliary; Pancreatic Neoplasms; Solid tumours | Details |
| Tegatrabetan | BC-2059; APL-121 | Phase 2 Clinical | Allergan Plc | Adenomatous Polyps; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Endometrial Neoplasms; Fibroma; Fibromatosis, Aggressive; Hepatoblastoma; Leukemia; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroblastoma; Osteosarcoma; Pancreatic Neoplasms; Sarcoma, Ewing; Solid tumours; Wilms Tumor | Details |
| Zolucatetide | Phase 2 Clinical | Parabilis Medicines Inc | Adenomatous Polyps | Details | |
| Urbagen gene addition therapy (CTNNB1 Foundation) | Phase 2 Clinical | CTNNB1 Foundation | Neurodevelopmental Disorders | Details | |
| Zolucatetide | FOG-001 | Phase 2 Clinical | Parabilis Medicines Inc | Adenomatous Polyposis Coli; Carcinoma, Hepatocellular; Colorectal Neoplasms; Craniopharyngioma; Endometrial Neoplasms; Fibromatosis, Aggressive; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| E-7386 | E-7386 | Phase 2 Clinical | Eisai Co Ltd, Prism Pharma Co Ltd | Carcinoma, Hepatocellular; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| DPTX-3186 | DPTX-3186; DPTX3186 | Phase 1 Clinical | Dewpoint Therapeutics Inc | Solid tumours | Details |
| ALN-BCAT | ALN-BCAT | Phase 1 Clinical | Alnylam Pharmaceuticals Inc | Carcinoma, Hepatocellular | Details |
| ST-316 | ST-316 | Phase 1 Clinical | Sapience Therapeutics Inc | Colonic Neoplasms; Hematologic Neoplasms; Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tetrandrine | NSC-77037; ES-3000; FF-0019 | Approved | Escend Pharmaceuticals Inc | Mainland China | Silicosis; Lung Neoplasms | null | 2015-05-19 | Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Myelodysplastic Syndromes; Silicosis | Details |
